



HYRIS **XTACT(SCV3)** Instruction for Use (IFU)

REF: R-XTACT(SCV3)-50

Version 1.3



INTENDED USE	4
SUMMARY AND EXPLANATION	4
PRINCIPLE OF THE PROCEDURE	5
MATERIALS PROVIDED	5
KIT DESCRIPTION	5
MATERIALS REQUIRED BUT NOT PROVIDED (available separately from Hyris)	6
OTHER MATERIALS REQUIRED BUT NOT PROVIDED (available separately from Hyris)	6
MATERIALS REQUIRED BUT NOT SUPPLIED	6
Hardware	6
Consumables	7
KIT STORAGE HANDLING AND STABILITY	7
Unopened/Once opened kit	7
SPECIMEN COLLECTION, TRANSPORT AND STORAGE	7
Specimen stability	7
WARNINGS AND PRECAUTIONS	8
OPERATING PROCEDURE	8
POOL PREPARATION	8
1. SAMPLE TREATMENT	9
1. SAMPLE INCUBATION	10
2. SAMPLE PREPARATION (Real -Time PCR)	10
RESULT INTERPRETATIONS	10
DATA EXPORT AND ANALYSIS	11
LIMITATIONS	13
BIBLIOGRAPHY	13
SYMBOLS DESCRIPTION	14



Hyris Srl
Corso Garibaldi, 60 20121
Milano (MI) Italy

Ordering informationE-mail: office@hyris.net

Phone: +39.02.82951302

Info on the productsE-mail: info@hyris.net**Technical assistance**E-mail: support@hyris.net

Phone: +39.02.82951302

Hyris Srl

Corso Garibaldi, 60 20121
Milano (MI) Italy

Visit our website at
www.hyris.net

INTENDED USE

The XTACT(SCV3) kit is intended for the ex vivo/in vitro stimulation of heparinized whole blood samples with a SARS-CoV-2 peptides pool covering the spike (S) protein, Nucleocapsid protein (NP) and regions of the protein S mutated into the omicron variant of SARS-CoV-2 virus.

The XTACT(SCV3) kit is a SARS-CoV-2 peptides pool intended to stimulate secretion of IFN- γ by antigen-specific T cells. *CXCL10* is a molecule expressed by monocytes in response to T cell activation. Monocytes and neutrophils are the main immune cells that increase the *CXCL10* mRNA production in response to IFN- γ .

The XTACT(SCV3) is intended to be used for research, monitoring and surveillance of the epidemiological status and on the immunization condition of the COVID-19 vaccinated population and individual with experienced previous contact with SARS-CoV-2 virus population.

The stimulated sample can be measured by one of the following methods: Real-Time PCR [Hyris bKIT™ dqTACT MS, bCUBE], ELISA, ELISpot, Flow-Cytometry.

Not to be used for diagnostic purposes.

For Research Use Only.

SUMMARY AND EXPLANATION

CXCL10 mRNA is upregulated by monocytes in response to IFN- γ secreted by antigen-specific T cells that have been stimulated with SARS-CoV-2 viral peptides in whole blood. *CXCL10* mRNA levels strongly correlate with the activation of antigen-specific T cells, serving as a "proxy" to quantify cellular immunity^[1].

T cell reactivity can be measured directly in fresh whole blood. T cells reactive against SARS-CoV-2 peptides overexpress cytokines (e.g. IFN- γ), which are released into the plasma. This response can be measured by the direct detection of IFN- γ (ELISA or flow cytometry) or *CXCL10* (RT-PCR)^[1]. Spike-specific T lymphocytes take about 10-12 days after vaccination to develop^[11] and persist for at least more than six months after infection however, what level of protection is conferred by the presence of T lymphocyte immune response needs to be fully elucidated^[11].

PRINCIPLE OF THE PROCEDURE

XTACT(SCV3), uses *three* synthetic peptide pools to activate cells against the Spike protein (POOL A), Nucleocapsid Protein (POOL B) and *Omicron variant mutated regions (POOL C)* of SARS-CoV-2.

XTACT(SCV3) can be used with fresh lithium heparinized whole blood.

The effective T cell activation can be measured after incubation by cytokine production and/or specific cytokine-related gene expression (i.e. *CXCL10* mRNA). Depending on the detection technique chosen (ELISA or flow cytometry) or *CXCL10* (RT-PCR) the sample preparation may vary slightly.

The XTACT(SCV3) kit can be used in combination with the bKIT™ dqTACT MS for the detection of *CXCL10* mRNA by RT-PCR either directly from whole blood or after RNA extraction.

MATERIALS PROVIDED

KIT DESCRIPTION

REF	Commercial name	Contents	Kit Size	Number of testable sample
R-XTACT(SCV3)-50	XTACT(SCV3)	SARS-CoV-2 protein peptides pool (reference strain) BUFFER R: peptide resuspension solution BUFFER C: cell culture buffered solution BUFFER A: buffered salt solution containing Tween 20%	POOL A: 1x44 µL POOL B SCV2: 1x44 µL POOL C SCV2: 1x44 µL POOL NEG SCV2: 1x44 µL BUFFER R SCV2: 1x1000µL BUFFER C SCV2: 3x4500µL	50
SRXTACTSCV2015 OBARB-200	Buffer A Box	Buffer A: buffered salt solution containing Tween 20% Dilution buffer: buffered salt solution	Buffer A SCV2: 6x4600µL Dilution buffer: 8x4480µL	50

MATERIALS REQUIRED BUT NOT PROVIDED (available separately from Hyris)

REF	Commercial name	Description	Size
Instruments			
bCUBE 2.0	bCUBE™	Miniaturized Thermal Cycler for PCR.	1 Instrument
H0001	bCUBE3	Miniaturized Thermal Cycler for PCR.	1 Instrument
Consumables			
HyCT16.01	HYRIS 16-well cartridges	Disposable 16-well cartridges for bCUBE™ Material: Ultra-pure polypropylene and aluminum	1 pack contains 25 cartridges
HyCT36.01	HYRIS 36-well cartridges	Disposable 36 well cartridges for bCUBE™ Material: Ultra-pure polypropylene and aluminum	1 pack contains 25 cartridges
Software			
bAPP	HYRIS bAPP™	Graphical User Interface (GUI) that works on smartphones, tablets, laptops, and PCs using any major operating system	-
Other reagents			
HR017X300	dqTACT MS	Real-Time PCR assay for the detection of <i>CXCL10</i> mRNA	300 reactions
SRXTACTSCV20150BARB-200	BUFFER A Box	BUFFER A: buffered salt solution containing Tween 20% DILUTION BUFFER: buffered salt solution	50 Test

OTHER MATERIALS REQUIRED BUT NOT PROVIDED (available separately from Hyris)

REF	Commercial name	Description	Note
Sk.1x-Acc.01	COVID Starter kit accessories	<ul style="list-style-type: none"> ● 3 x Precision pipettes (10µL, 100 µL, 1000 µL) ● 1 x Mini centrifuge ● 1 x Mini vortex 	Customizable on the basis of Laboratory needs.

MATERIALS REQUIRED BUT NOT SUPPLIED
Hardware

- Incubator for cell culture at 37±1°C (with or without CO₂)
- PC, tablet, or smartphone with Google Chrome or compatible browser
- 2 to 8°C refrigerator for thawing operation (or cooler bag for transport) Freezer from -10 to -30 °C for storage
- Vortex mixer at minimum 3000 rpm
- Micropipette 200µL
- Racks for 1.5 mL microcentrifuge tubes
- PPE such as (but not limited to) respiratory protection (facemask), safety goggles, full length long (elastic) sleeved lab coat, and suitable disposable gloves.

Consumables

- Sterile DNase/RNase free, filter tips 10µL
- Sterile DNase/RNase free, filter tips 100µL
- Sterile DNase/RNase free, filter tips 200µL
- Sterile DNase/RNase free, filter tips 1000µL
- 2mL Sterile, nonpyrogen, RNase DNase free, polypropylene microcentrifuge tubes
- Surface decontaminants like for instance RNase AWAY™ (Thermo Scientific Cat# 7002PK) or equivalent

KIT STORAGE HANDLING AND STABILITY

The XTACT(SCV3) kit is shipped refrigerated (cold packs).

Unopened/Once opened kit

Store the reagents included in the HYRIS XTACT(SCV3) at the following temperatures:

- POOL A, POOL B, POOL C and POOL NEG between 2°C and 8°C
- BUFFER C and BUFFER R between 2°C and 8°C

BUFFER A (SRXTACTSCV20150BARB-200) at Room Temperature (RT).

Allow the reagents at room temperature before the use.

SPECIMEN COLLECTION, TRANSPORT AND STORAGE

The HYRIS XTACT(SCV3) kit is designed to work with whole blood specimens collected with lithium heparin tubes used for plasma determination in chemistry. Proper specimen collection, storage, and transport are critical to the performance of this test. Inadequate specimen collection, handling, and/or transport may yield a false result. Handle specimens as if they are capable of transmitting infection agents.

The HYRIS XTACT(SCV3) kit has been validated on the following matrix: whole blood sample.

Table 1 reports the compatible collection and transport systems validated on the HYRIS bKIT™ XTACT(SCV3).

<i>Compatible collection and transport system</i>	<i>Cap Color</i>	<i>Tube size</i>	<i>Volume (mL)</i>
Lithium heparin sterile single blood collection tube (BD Vacutainer® REF# 368886)	Green	13x100	6.0

Table 1 - list of all validated collection methods

The XTACT(SCV3) kit has been validated with the lithium heparin tube BD Vacutainer® REF# 368886.

WARNING: Tubes used for blood collection must be inverted several times immediately after collection and before processing. Insufficient mixing at this step will negatively impact sample quality.

Specimen stability

Whole blood must be treated with the HYRIS XTACT(SCV3) within 6-8 hours from collection. Whole blood should be kept at room temperature up to 6-8 hours after collection.

Do not freeze the blood or *keep it at 4°C before stimulation with the XTACT(SCV3).*

After stimulation with XTACT(SCV3), samples must be immediately analyzed and/or immediately stored at -80°C *after the immediate dilution of stimulated blood with BUFFER A (see sample preparation paragraph).*

WARNINGS AND PRECAUTIONS

- For research use only (RUO);
- For Professional User;
- Wear personal protective equipment, such as (but not limited to) gloves, and lab coats when handling kit reagents and equipment. Wash hands thoroughly when finished performing the test;
- Do not pipette by mouth
- Do not smoke, drink, eat, handle contact lenses, or apply make-up in areas where kit reagents and/or human specimens are being used;
- Dispose of unused kit reagents and human specimens as hazardous waste for incineration according to local, state, and federal regulations;
- Treat all human specimens and all consumables that have come into contact with the samples included the cartridge as capable of transmitting infectious agents;
- Contamination of patient specimens or reagents can produce erroneous results. Use good laboratory practices and control workflow;
- Only use the protocol described in this insert. Deviations from the protocol or the use of times or temperatures other than those specified may give erroneous results;
- Assay setup should be performed at room temperature (approximate range 18 to 25°C);
- Do not use kits or reagents beyond their expiration dates.
- Do not use the kits or reagents if are received with primary or secondary packaging visually compromised or in warm conditions and contact the Hyris support (support.hyris.net) immediately
- Use calibrated micro pipettes to transfer sample and reagents
- Avoid touching the adhesive side of the aluminum foil that will be in contact with the HYRIS bCUBE™ cartridge;
- Protect reagents from direct sources of light;
- Safety Data Sheets (SDS) are provided for each reagent upon request;

OPERATING PROCEDURE

WARNING: clean all the surfaces and instruments, including the external of HYRIS bCUBE™, before and after the analytical procedure with sodium hypochlorite (0.5%) wipes.

POOL PREPARATION

- a. Let the reagents at room temperature before use (between 18°C and 25°C)
- b. Resuspend the POOL A, POOL B **SCV2**, POOL C **SCV2** and POOL NEG **SCV2** with the BUFFER R included into the XTACT(SCV3) kit prior the first use according with the **table 2 below**. add 176µL of BUFFER R to the POOL A, POOL B **SCV2**, POOL C **SCV2**, POOL NEG **SCV2** and mix well.

Pool of peptides	BUFFER R volume
POOL A	176µL
POOL B SCV2	176µL
POOL C SCV2	176µL
POOL NEG SCV2	176µL

Table 2 – Buffer R volumes to resuspend peptide pools at first use

1. SAMPLE TREATMENT

WARNING: mix well with a vortex (3000rpm) the peptides pool before the use

Before activating the samples, clean all instruments and work surfaces.

- a. For each sample prepare 4 sterile polypropylene tubes and label them as follows:
 - i. "POOL A" on the first tube.
 - ii. "POOL B" on the second tube.
 - iii. "POOL C" on the third tube.
 - iv. "POOL NEG" on the fourth tube.
 - v. Report the sample ID on all tubes.
- b. Add 4 µL of POOL A to the "POOL A" labeled tube of each sample then discard the tip
- c. Add 4 µL of POOL B **SCV2** to the "POOL B" labeled tube of each sample then discard the tip
- d. Add 4 µL of POOL C **SCV2** to the "POOL C" labeled tube of each sample then discard the tip
- e. Add 4 µL of POOL NEG **SCV2** to the "POOL NEG" labeled tube of each sample then discard the tip.
- f. Add 80 µL of BUFFER C **SCV2** to all tubes ("POOL A" and "POOL B" and "POOL C" and "POOL NEG" labeled tubes) changing tips between tubes
- g. Add 320 µL of whole fresh blood to all tubes ("POOL A" and "POOL B" and "POOL C" and "POOL NEG" labeled tubes) changing tips between tubes
- h. Gently mix the blood 2-3 times with the 1000µL micropipette (keeping the volume at 320µL) changing tips between tubes.

Table 3 summarizes the sample activation workflow (how to manage specimens, tubes, and reagents)

WARNING: be sure to have added the pool of peptides to the bottom of the tubes prior the blood addition. Blood, peptides and BUFFER C should be well mixed at the bottom of the tube prior to incubation.

Specimen ID	Sample Pool tube	Pool of peptides	BUFFER C (µL)	Whole blood (µL)	Final volume into the 1.5 mL tube (µL)
1	1 POOL A	4 µL of POOL A	80	320	404
	1 POOL B	4 µL of POOL B SCV2	80	320	404
	1 POOL C	4 µL of POOL C SCV2	80	320	404
	1 POOL NEG	4 µL POOL NEG SCV2	80	320	404
2	2 POOL A	4 µL of POOL A	80	320	404
	2 POOL B	4 µL of POOL B SCV2	80	320	404
	2 POOL C	4 µL of POOL C SCV2	80	320	404
	2 POOL NEG	4 µL POOL NEG SCV2	80	320	404
...
n	n POOL A	4 µL of POOL A	80	320	404
	n POOL B	4 µL of POOL B SCV2	80	320	404
	n POOL C	4 µL of POOL C SCV2	80	320	404
	n POOL NEG	4 µL POOL NEG SCV2	80	320	404

Table 3 - Sample preparation workflow

1. SAMPLE INCUBATION

- a. Keep the cap of the polypropylene loose to allow the air exchange.
- b. Incubate tubes overnight tubes at +37±1°C (time of incubation: 12h-18h).

2. SAMPLE PREPARATION (Real -Time PCR)

- a. After the overnight incubation, vortex the tubes for 10 seconds at 3200 rpm.
- b. For each sample take 4 new sterile microcentrifuge tubes and label them as follows:
 - i. "POOL A" on the first tube
 - ii. "POOL B" on the second tube.
 - iii. "POOL C" on the third tube.
 - iv. "POOL NEG" on the fourth tube.
 - v. Report the sample ID on all tubes.
- c. Add 40 µL of stimulated blood to each tube ("POOL A" and "POOL B" and "POOL C" and "POOL NEG" labeled tubes) changing tips between tubes
- d. Add 120 µL of buffer A to all tubes ("POOL A" and "POOL B" and "POOL NEG" labeled tubes) changing tips between tubes
- e. Mix well the tubes with a vortex at 3000 rpm for 10s
- f. Process immediately with the **bKIT™ dqTACT MS** (Refer to IFU of the **HYRIS bKIT™ dqTACT MS**).

WARNING: If immediate processing is not possible, freeze the treated samples + BUFFER A at -80°C immediately.

Table 4 summarizes the sample preparation workflow (how to manage specimens, tubes, and reagents).

Sample ID	Activated blood (µL)	Buffer A (µL)	Total volume into the 1.5 mL tube (µL)
1 POOL A	40	120	160
1 POOL B	40	120	160
1 POOL NEG	40	120	160
....
n	40	120	160

Table 4 – Sample preparation workflow

WARNING: Whether the sample stimulation result is measured by one of the following methods: ELISA, ELISpot, Flow-Cytometry, refer to the manufacturer instruction for use.

RESULTS INTERPRETATION

*Interpretation of results is automatically performed by HYRIS bAPP for samples analyzed with the **bKIT™ dqTACT MS** kit used on **HYRIS bcUBE**. The "RESULTS" tab will display the final result.*

*In case the analysis is performed on other instruments, it is recommended to follow the procedure given in the "DATA EXPORT AND ANALYSIS" section of the instructions for use of the **bKIT™ dqTACT MS**. *Table 5* shows the Ct cut-off obtained by the analysis with the kit **bKIT™ dqTACT MS**.*

Real Time PCR Ct cutoff		
Sample	TARGET	Ct cutoff
SAMPLE	CXCL10	Valid for Ct ≤42
	ACTIN	Valid for Ct ≤33

Table 5 - bKIT™ dqTACT MS Ct cut-off

Using the HYRIS bKIT™ dqTACT MS on the HYRIS bCUBE with the HYRIS bAPP, the results are automatically calculated and expressed in terms of reactivity.

Table 6 shows the interpretation of the single sample test result after the data analysis and calculation:

bKIT™ dqTACT MS RESULTS		
bAPP RESULTS	Relative mRNA expression of CXCL10	T CELL ANTIGEN SPECIFIC REACTIVITY
NOT REACTIVE	< 0.001	NOT RESPONSIVE to specific-peptides pool stimulation
REACTIVE	> 0.003	RESPONSIVE to specific-peptides pool stimulation
BORDERLINE REACTIVITY	0.001 ≤ x ≤ 0.003	BORDERLINE RESPONSIVE to specific-peptides pool stimulation
INCONCLUSIVE	-	INCONCLUSIVE the ACTIN Ct into the stimulated sample is over the Ct Cut-off
INVALID	-	INVALID One of the controls DOES NOT exhibit the expected performance and the analysis CAN NOT be consider valid. Repeat the analysis

Table 6 - bKIT™ dqTACT MS interpretation table result

If inconclusive and invalid results persist, contact Hyris technical support at support.hyris.net

The CXCL10 relative mRNA expression calculation is based on the delta-delta Ct method. A sample is considered reactive to the peptide pool stimulation when the relative CXCL10 mRNA expression is above 0.003.

DATA EXPORT AND ANALYSIS

Follow this procedure if you are working with a Bio-Rad CFX-96

To interpret the results, follow these steps:

- download the analysis Excel report file from support.hyris.net
- download the results interpretation file, for instance "dqTACT for XTACT(SCV3&4) interpretation_V xx.xlsx".
- insert Ct values into the "Data insertion" sheet of the interpretation file coping the FAM and HEX Ct values of each sample from the analysis report file.
- Copy the FAM and HEX Ct values from the analysis report Excel sheet into the "Data insertion" tab of the dqTACT for XTACT(SCV3&4) Interpretation file.
- The "Interpreted Result" tab will display the final result.

Hyris Srl recommends a phased approach for the interpretation of the results with the Real Time PCR method.

Phase one, verification of the validity of the Positive and Negative controls of the test. Once this validity is established, the data can be interpreted.

Phase two, verification of the validity of the internal control value (ACTIN), an indication of the presence of sufficient cellular material for analysis. Ct values of ACTIN less than 33 are accepted.

Phase three, final data interpretation stage, in which the sample response to stimulation by the peptide pools is evaluated. Stimulation is evaluated by considering the Ct values of CXCL10 and ACTIN obtained by treatment with the peptide pools (treated sample) and those obtained with the sample stimulated with POOL NEG SCV2 (untreated sample)

Phase four, the change of CXCL10 in stimulated samples, by subtraction of the BASE value, on the post-vaccination immune reaction is evaluated.









LIMITATIONS

1. For research use only.
2. For Professional User
3. This test is a qualitative test and does not provide quantitative value of the T-Cells responsivity.
4. *Some non-reactive results may occur if the analyte is present at a lower level than the analytical sensitivity of the assay.*
5. *This test is qualitative and does not provide a quantitative value for T cell reactivity*
6. *The test result is related to the collection, handling, delivery and storage of the specimen. Any deviation from the indicated procedure will lead to an inaccurate detection result.*
7. *The result depends on the accuracy of sample collection and storage*
8. *Using blood collection systems other than those indicated will compromise the result*
9. *The use of unsuitable tools can compromise the results*
10. *The use of consumable non-sterile, pyrogen, endotoxin free can compromise the result*
11. *Vortex mixers that do not reach 3200rpm, as well as insufficient mixing times can affect the results of the procedure.*

BIBLIOGRAPHY

1. M. Schwarz, et al., *Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology July 2022.*
2. Le Bert, N. et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med* 218 (2021).
3. Tan AT, Lim JM, Le Bert N, Kunasegaran K, Chia A, Qui M et al. Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected. *bioRxiv* 2021; 2021.06.29.450293
4. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med* 2021; 218. doi:10.1084/jem.20202617
5. Kalimuddin S, Tham CY, Qui M, de Alwis R, Sim JX, Lim JM et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. *Med (N Y)* 2021; 2: 682-688.e4
6. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* 2020; 584: 457–462.
7. Tan, A. T. et al. Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Reports* 34, 108728 (2021). doi: 10.1016/j.celrep.2021.108728
8. Tan A.T. et al. Rapid measurement of SARS-CoV-2 spike T cell in whole blood from vaccinated and naturally infected individuals. *Journal of Clinical Investigation*. doi: 10.1172/JCL152379
9. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020; 5(4): 536-44 .
10. Lozano-Ojalvo D, Camara C et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. *Cell Rep.* 2021 Aug 24;36(8):109570. doi: 10.1016/j.celrep.2021.109570. Epub 2021 Aug 4. PMID: 34390647; PMCID: PMC8332924.

SYMBOLS DESCRIPTION

SYMBOL	DESCRIPTION
	LOT
	Catalog number
	Expiration date
	Manufacturer
	Refer to the instructions for Use/functioning.
	Content sufficient for <n> test
	Temperature range recommended
	Do not use if the cold aging is broken

Released: 27 October 2022

The XTACT(SCV3) have been internally tested by our quality control. Any responsibility is waived for any use of label. HYRIS bCUBE™, HYRIS bAPP™ and HYRIS bKIT™ are a trademark of HYRIS S.r.l.